This study is completed in the United States, in Bulgaria, in Czechia, .... It is testing NBI-1065845 for depression.
DepressionDrugFrom 18 Years to 65 Years
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Then choose your country and confirm availability with each study site.
In plain English
Key information made simple
What is this study testing?
This study is testing whether NBI-1065845 may be useful for adults experiencing depression.
What would participation involve?
Participants may receive NBI-1065845, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in Bulgaria, in Czechia, and in Poland.
Who is it mainly for?
This study appears to be mainly for adults with depression.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.
Your next step
Check the study details
Check the official source, then confirm these points with the research team.
Where are visits, can any be remote, and how much time is needed?
Costs and support
What costs, reimbursement or compensation apply?
Before joining
Questions to ask before joining
What are the exact eligibility criteria, and what could exclude someone?
How many visits, assessments, or follow-ups are expected, and over what period?
What risks, side effects, practical burdens, or alternatives should be understood first?
Who should be contacted to confirm locations, timing, compensation, and next steps?
Study clarity
Things to check before joining
Study start dateStarted: February 21, 2022
Recruitment status
Completed
Enrollment listed in the registry
183
Sponsor
Neurocrine Biosciences
Sponsor type
Biotech company
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States, Bulgaria, Czechia, ...
Age range
From 18 Years to 65 Years
Official registry ID
NCT05203341
Official title
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-1065845 in Adult Subjects With Major Depressive Disorder (MDD)
Ask HopeStage to help me review this study
This record does not confirm open recruitment. We can help you understand it and explore other studies.
Study ID: NCT05203341. We help you review the study, but cannot decide medical eligibility.
Check recruitment and locations
Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.
The overall study status can differ from each site's status. Open a country to see its locations and their registry status.
Bulgaria · 7 sites
Neurocrine Clinical Site
Plovdiv
Site status: Not listed — confirm with the team
Neurocrine Clinical Site
Rousse
Site status: Not listed — confirm with the team
Neurocrine Clinical Site
Sofia
Site status: Not listed — confirm with the team
Neurocrine Clinical Site
Tsarev Brod
Site status: Not listed — confirm with the team
Neurocrine Clinical Site
Varna
Site status: Not listed — confirm with the team
Neurocrine Clinical Site
Veliko Tarnovo
Site status: Not listed — confirm with the team
Neurocrine Clinical Site
Vratsa
Site status: Not listed — confirm with the team
Czechia · 5 sites
Neurocrine Clinical Site
Kladno
Site status: Not listed — confirm with the team
Neurocrine Clinical Site
Pilsen
Site status: Not listed — confirm with the team
Neurocrine Clinical Site
Prague
Site status: Not listed — confirm with the team
Neurocrine Clinical Site
Prague
Site status: Not listed — confirm with the team
Neurocrine Clinical Site
Prague
Site status: Not listed — confirm with the team
Poland · 4 sites
Neurocrine Clinical Site
Bełchatów
Site status: Not listed — confirm with the team
Neurocrine Clinical Site
Chełmno
Site status: Not listed — confirm with the team
Neurocrine Clinical Site
Gdansk
Site status: Not listed — confirm with the team
Neurocrine Clinical Site
Katowice
Site status: Not listed — confirm with the team
Slovakia · 4 sites
Neurocrine Clinical Site
Košice
Site status: Not listed — confirm with the team
Neurocrine Clinical Site
Rimavská Sobota
Site status: Not listed — confirm with the team
Neurocrine Clinical Site
Trenčín
Site status: Not listed — confirm with the team
Neurocrine Clinical Site
Vranov nad Topľou
Site status: Not listed — confirm with the team
Sweden · 4 sites
Neurocrine Clinical Site
Gothenburg
Site status: Not listed — confirm with the team
Neurocrine Clinical Site
Halmstad
Site status: Not listed — confirm with the team
Neurocrine Clinical Site
Lund
Site status: Not listed — confirm with the team
Neurocrine Clinical Site
Stockholm
Site status: Not listed — confirm with the team
United States · 17 sites
Neurocrine Clinical Site
Birmingham, Alabama
Site status: Not listed — confirm with the team
Neurocrine Clinical Site
Huntsville, Alabama
Site status: Not listed — confirm with the team
Neurocrine Clinical Site
Riverside, California
Site status: Not listed — confirm with the team
Neurocrine Clinical Site
San Diego, California
Site status: Not listed — confirm with the team
Neurocrine Clinical Site
San Francisco, California
Site status: Not listed — confirm with the team
Neurocrine Clinical Site
Torrance, California
Site status: Not listed — confirm with the team
Neurocrine Clinical Site
Hartford, Connecticut
Site status: Not listed — confirm with the team
Neurocrine Clinical Site
Palmetto Bay, Florida
Site status: Not listed — confirm with the team
Neurocrine Clinical Site
Gaithersburg, Maryland
Site status: Not listed — confirm with the team
Neurocrine Clinical Site
Weldon Spring, Missouri
Site status: Not listed — confirm with the team
Neurocrine Clinical Site
Columbus, Ohio
Site status: Not listed — confirm with the team
Neurocrine Clinical Site
North Canton, Ohio
Site status: Not listed — confirm with the team
Neurocrine Clinical Site
Oklahoma City, Oklahoma
Site status: Not listed — confirm with the team
Neurocrine Clinical Site
Memphis, Tennessee
Site status: Not listed — confirm with the team
Neurocrine Clinical Site
Dallas, Texas
Site status: Not listed — confirm with the team
Neurocrine Clinical Site
Houston, Texas
Site status: Not listed — confirm with the team
Neurocrine Clinical Site
Draper, Utah
Site status: Not listed — confirm with the team
In practice
For you
Participation may contribute to research. Personal benefit is not guaranteed.
Ask the research team to explain the activities, time commitment, and follow-up involved.
Study sites are listed. Confirm the relevant site and any travel before making plans.
Important
Not medical advice
Information from public sources.
Are you the study sponsor? Contact us to update this page: hi@hopestage.com
FAQ
Questions about this study
What is this study trying to understand?
This study is exploring medication or study treatment for people with depression. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Does this study involve a medication?
This appears to be a medication / drug study involving Placebo, NBI-1065845. Phase 2 studies usually explore whether the intervention may work, while continuing to monitor safety.
Who might this study be for?
This study may concern people with depression; age range: From 18 Years to 65 Years. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What side effects, interactions, or treatment changes should I check?
If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by Neurocrine Biosciences, which appears to be a biotech company. Sponsor website: https://www.neurocrine.com. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Explore other studies
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
